Abstract According to the Alzheimer Association Report (2017), Alzheimer's disease (AD) is
the 6th primary cause of death in the USA, which affects nearly 5.5 million people. In the …

Alzheimer's disease (AD): AD, a neurodegenerative disorder and a significant cause of
dementia throughout the world mostly affects the older adults but sometimes also seen in …

The Alzheimer's disease is a neurodegenerative condition with severe consequences
interfering with patient quality of life. It is characterized as a progressive and irreversible …

Although the global prevalence of neurological disorders such as Parkinson's disease,
Alzheimer's disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing …

Alzheimer's disease (AD) is a chronic and progressive age-related irreversible
neurodegenerative disorder that represents 70% of all dementia with 35 million cases …

Nose-to-brain delivery represents a big challenge. In fact there is a large number of
neurological diseases that require therapies in which the drug must reach the brain …

The treatment of brain disorders is the greatest challenge because of a variety of formidable
obstacles in effective drug delivery and maintaining therapeutic concentrations in the brain …

Despite the increasing global incidence of brain disorders, achieving sufficient delivery
towards the central nervous system (CNS) remains a formidable challenge in terms of …

Parkinson's disease (PD) is the second leading neurodegenerative disease globally,
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …

Now a day's intranasal (in) drug delivery is emerging as a reliable method to bypass the
blood–brain barrier (BBB) and deliver a wide range of therapeutic agents including both …